• Laura A A Gilliam, Jennifer S Moylan, Leigh Ann Callahan, Marius P Sumandea, and Michael B Reid.
• Department of Physiology, University of Kentucky, 800 Rose Street, MS-508, Lexington, Kentucky 40536-0298, USA.
• Muscle Nerve. 2011 Jan 1;43(1):94-102.

AbstractDoxorubicin is a chemotherapeutic agent prescribed for a variety of tumors. While undergoing treatment, patients exhibit frequent symptoms that suggest respiratory muscle weakness. Cancer patients can receive doxorubicin chemotherapy through either intravenous (IV) or intraperitoneal (IP) injections. We hypothesized that respiratory muscle function would be depressed in a murine model of chemotherapy. We tested this hypothesis by treating C57BL/6 mice with a clinical dose of doxorubicin (20 mg/kg) via IV or IP injection. Three days later we measured contractile properties of muscle fiber bundles isolated from the diaphragm. Doxorubicin consistently depressed diaphragm force with both methods of administration (P < 0.01). Doxorubicin IP exaggerated the depression in diaphragm force and stimulated tissue inflammation and muscle fiber injury. These results suggest that clinically relevant doses of doxorubicin cause respiratory muscle weakness and that the loss of function depends, in part, on the route of administration.Copyright © 2010 Wiley Periodicals, Inc.

27 keywords...

hide…